Medical Centre Synexus Sofia EOOD — Clinical Trial Site

19 Registered trials

3 Currently recruiting

Organisation

Medical Centre Synexus Sofia EOOD

Location

Sofia, Bulgaria

Identifier

ORG-100040905

Address

Mladost, Bul Andrey Saharov 20a, 1784, Bulgaria

Departments

#2100: Office of rheoumatology
#2212
#7202:
0909; NA
Medical center Synexus Sofia
Medical Center Synexus Sofia EOOD
N/A
NA
Office of gastroenterology
Physician Office of Rheumatology
Pulmonology and Phtisiatrics
Rheumatology and Internal Disease

Clinical trials at this site (19)

Search interface

A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil… Not authorised

2022-501361-44-00 Adult patients of either gender with active moderate to 5
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Sm… Recruiting

2023-504595-26-00 Non-Small Cell Lung Cancer 4 2023-05-22
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the i… Recruiting

2023-504417-67-00 Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiog 6 2020-12-22
ATHENA: A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation Ended

2023-506988-34-00 Heart failure with mildly reduced or preserved ejection 5 2024-03-27
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08
Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat… Ended

2023-508170-28-00 alcohol-related liver disease 4 2024-08-07
A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi… Ended

2022-501421-20-00 Gout with hyperuricemia 5 2024-04-09
A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and … Ended

2022-502778-18-00 ulcerative colitis 5 2023-11-17
BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria Ended

2024-514764-72-00 Chronic Urticaria 5 2023-09-27
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended

2022-502234-70-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-07-14
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Severe hypertryglyceridemia 5 2023-05-17
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel… Ended

2023-509243-27-00 Moderate-to-Severe Uncontrolled Asthma 4 2023-04-12
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Ch… Ended

2024-516988-87-00 Chronic Inducible Urticaria 4 2022-11-09
Open-label trial to check the safety and tolerability of RTX-GRT7039 injections for pain associated with osteoarthritis of the knee. Ended

2024-515709-24-00 Moderate to severe pain associated with Osteoarthritis 5 2022-07-26
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended

2024-511553-22-00 Moderately to Severely Active Crohn's Disease 5 2018-10-05
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can… Ended

2024-517856-36-00 Completely resected primary stage IB (≥ 4cm), II and II 5 2015-03-09
A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and… Ended

2024-512417-41-00 Osteoporosis 5